Trial Profile

A Phase 2a Study to Evaluate Safety and Tolerability After Single Administration of PER-001 Intravitreal Implant in Participants With Diabetic Retinopathy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PER 001 (Primary)
Indications Diabetic retinopathy
Focus Adverse reactions; Therapeutic Use
Sponsors Perfuse Therapeutics

Most Recent Events

24 Jun 2025 According to a Perfuse Therapeutics media release, data from this study was presented at Clinical Trials at the Summit (CTS) meeting on June 21.
24 Jun 2025 The 24-week data presented in the Perfuse Therapeutics Media Release.
15 Apr 2025 Planned End Date changed from 31 May 2026 to 1 Apr 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com